Bisphosphonates and Bone Quality

Overview

Journal Bonekey Rep

Date 2014 May 31

PMID 24876930

Citations 49

Authors

Michael Pazianas

Stefan van der Geest

Paul Miller

Affiliations

Soon will be listed here.

Abstract

Bisphosphonates (BPs) are bone-avid compounds used as first-line medications for the prevention and treatment of osteoporosis. They are also used in other skeletal pathologies such as Paget's and metastatic bone disease. They effectively reduce osteoclast viability and also activity in the resorptive phase of bone remodelling and help preserve bone micro-architecture, both major determinants of bone strength and ultimately of the susceptibility to fractures. The chemically distinctive structure of each BP used in the clinic determines their unique affinity, distribution/penetration throughout the bone and their individual effects on bone geometry, micro-architecture and composition or what we call 'bone quality'. BPs have no clinically significant anabolic effects. This review will touch upon some of the components of bone quality that could be affected by the administration of BPs.

Citing Articles

Bone Disease in Primary Hyperparathyroidism-Changes Occurring in Bone Metabolism and New Potential Treatment Strategies.

Iwanowska M, Kochman M, Szatko A, Zgliczynski W, Glinicki P Int J Mol Sci. 2024; 25(21).

PMID: 39519190 PMC: 11546563. DOI: 10.3390/ijms252111639.

PET/CT for the Opportunistic Screening of Osteoporosis and Fractures in Cancer Patients.

Park P, Werner T, Alavi A Curr Osteoporos Rep. 2024; 22(6):553-560.

PMID: 39276167 DOI: 10.1007/s11914-024-00887-x.

Clinically relevant doses of tiludronate do not affect bone remodelling in pasture-exercised horses.

Tippen S, Metzger C, Sacks S, Allen M, Mitchell C, McNulty M Equine Vet J. 2024; 57(2):513-521.

PMID: 38924597 PMC: 11807941. DOI: 10.1111/evj.14119.

Association between perioperative blood transfusion and length of hospital stay in patients with osteoporotic fractures.

Xu S, Lu K, Yang X, Ye Y, Xu M, Shi Q BMC Musculoskelet Disord. 2023; 24(1):982.

PMID: 38114943 PMC: 10729380. DOI: 10.1186/s12891-023-07101-6.

Biologics: Teriparatide and Newer Anabolics.

Jha S Indian J Orthop. 2023; 57(Suppl 1):135-146.

PMID: 38107803 PMC: 10721587. DOI: 10.1007/s43465-023-01063-6.

References

Fuchs R, Phipps R, Burr D . Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats. J Bone Miner Res. 2008; 23(10):1689-97. PMC: 2684160. DOI: 10.1359/jbmr.080501. View

Seeman E, Delmas P . Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med. 2006; 354(21):2250-61. DOI: 10.1056/NEJMra053077. View

Allen M, Iwata K, Sato M, Burr D . Raloxifene enhances vertebral mechanical properties independent of bone density. Bone. 2006; 39(5):1130-1135. DOI: 10.1016/j.bone.2006.05.007. View

Borah B, Gross G, Dufresne T, Smith T, Cockman M, Chmielewski P . Three-dimensional microimaging (MRmicroI and microCT), finite element modeling, and rapid prototyping provide unique insights into bone architecture in osteoporosis. Anat Rec. 2001; 265(2):101-10. DOI: 10.1002/ar.1060. View

Zebaze R, Ghasem-Zadeh A, Bohte A, Iuliano-Burns S, Mirams M, Price R . Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet. 2010; 375(9727):1729-36. DOI: 10.1016/S0140-6736(10)60320-0. View

Monroe D, McGee-Lawrence M, Oursler M, Westendorf J . Update on Wnt signaling in bone cell biology and bone disease. Gene. 2011; 492(1):1-18. PMC: 3392173. DOI: 10.1016/j.gene.2011.10.044. View

Green J, Diab T, Allen M, Vidakovic B, Burr D, Guldberg R . Three years of alendronate treatment does not continue to decrease microstructural stresses and strains associated with trabecular microdamage initiation beyond those at 1 year. Osteoporos Int. 2012; 23(9):2313-20. DOI: 10.1007/s00198-011-1875-8. View

Plotkin L, Manolagas S, Bellido T . Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone. 2006; 39(3):443-52. DOI: 10.1016/j.bone.2006.02.060. View

Borah B, Dufresne T, Chmielewski P, Gross G, Prenger M, Phipps R . Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res. 2002; 17(7):1139-47. DOI: 10.1359/jbmr.2002.17.7.1139. View

10.

Burket J, Brooks D, MacLeay J, Baker S, Boskey A, van der Meulen M . Variations in nanomechanical properties and tissue composition within trabeculae from an ovine model of osteoporosis and treatment. Bone. 2012; 52(1):326-36. PMC: 3612543. DOI: 10.1016/j.bone.2012.10.018. View

11.

Augat P, Schorlemmer S . The role of cortical bone and its microstructure in bone strength. Age Ageing. 2006; 35 Suppl 2:ii27-ii31. DOI: 10.1093/ageing/afl081. View

12.

Keaveny T, Hoffmann P, Singh M, Palermo L, Bilezikian J, Greenspan S . Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res. 2008; 23(12):1974-82. PMC: 2686921. DOI: 10.1359/jbmr.080805. View

13.

Macias B, Swift J, Nilsson M, Hogan H, Bouse S, Bloomfield S . Simulated resistance training, but not alendronate, increases cortical bone formation and suppresses sclerostin during disuse. J Appl Physiol (1985). 2011; 112(5):918-25. DOI: 10.1152/japplphysiol.00978.2011. View

14.

Dempster D . The contribution of trabecular architecture to cancellous bone quality. J Bone Miner Res. 2000; 15(1):20-3. DOI: 10.1359/jbmr.2000.15.1.20. View

15.

Weinstein R, Roberson P, Manolagas S . Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009; 360(1):53-62. PMC: 2866022. DOI: 10.1056/NEJMoa0802633. View

16.

Roschger P, Gupta H, Berzlanovich A, Ittner G, Dempster D, Fratzl P . Constant mineralization density distribution in cancellous human bone. Bone. 2003; 32(3):316-23. DOI: 10.1016/s8756-3282(02)00973-0. View

17.

Guy J, Shea M, Peter C, Morrissey R, Hayes W . Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int. 1993; 53(4):283-8. DOI: 10.1007/BF01320915. View

18.

Borah B, Dufresne T, Chmielewski P, Johnson T, Chines A, Manhart M . Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone. 2004; 34(4):736-46. DOI: 10.1016/j.bone.2003.12.013. View

19.

Chavassieux P, Arlot M, Reda C, Wei L, Yates A, Meunier P . Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997; 100(6):1475-80. PMC: 508326. DOI: 10.1172/JCI119668. View

20.

Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T . Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 2006; 4(2):111-21. DOI: 10.1016/j.cmet.2006.05.012. View